Janux Therapeutics’ (JANX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Janux Therapeutics (NASDAQ:JANX) in a report released on Thursday,Benzinga reports. The brokerage currently has a $63.00 price target on the stock.

Several other research firms also recently commented on JANX. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a report on Thursday. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. UBS Group started coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. Wedbush restated an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Scotiabank cut their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Trading Up 0.8 %

Shares of NASDAQ JANX traded up $0.46 during midday trading on Thursday, hitting $54.67. The company’s stock had a trading volume of 569,743 shares, compared to its average volume of 712,373. The business’s 50 day moving average is $48.88 and its two-hundred day moving average is $46.35. Janux Therapeutics has a 12-month low of $5.65 and a 12-month high of $65.60. The firm has a market cap of $2.85 billion, a P/E ratio of -46.33 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business’s revenue was down 82.6% compared to the same quarter last year. On average, analysts predict that Janux Therapeutics will post -1.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the sale, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the company’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $50.02, for a total value of $92,186.86. Following the sale, the insider now owns 6,371 shares in the company, valued at $318,677.42. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00. Following the transaction, the chief executive officer now owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 420,610 shares of company stock worth $19,288,666 in the last three months. Corporate insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently made changes to their positions in JANX. Summit Securities Group LLC acquired a new position in shares of Janux Therapeutics in the second quarter worth about $29,000. Amalgamated Bank boosted its position in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd purchased a new position in Janux Therapeutics during the second quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Janux Therapeutics in the second quarter valued at approximately $151,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.